Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Weighted Average) (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $108.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 9.64% to $108.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.4 million through Dec 2025, up 9.64% year-over-year, with the annual reading at $108.4 million for FY2025, 9.64% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $108.4 million at Intellia Therapeutics, up from $105.8 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $108.4 million in Q4 2025, with the low at $67.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $87.5 million, with a median of $88.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 35.94% in 2021, then grew 3.18% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $70.9 million in 2021, then grew by 8.57% to $77.0 million in 2022, then increased by 15.33% to $88.8 million in 2023, then rose by 11.35% to $98.8 million in 2024, then rose by 9.64% to $108.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $108.4 million, $105.8 million, and $103.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.